NEW YORK, Jan. 12, 2022 /PRNewswire/ — Technavio’s latest research report on the Microbial Products Market offers a comprehensive analysis of new product launches, the latest trends, drivers, and challenges. 41% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for microbial products in North America. However, the market growth rate in this region will be slower than the growth of the market in the European and Asian regions. The increasing focus on microbe-based clinical research and the growing prevalence of new infectious diseases will facilitate the microbial products market growth in North America over the forecast period.
The microbial products market is estimated to grow by USD 18.41 billion from 2021 to 2026, growing at a CAGR of 12.20% as per the latest market research report by Technavio.
For more insights on the microbial products market –Download a free sample now!
Market Dynamics
The market is driven by factors such as the high demand for microbial products in the pharmaceutical industry, advances in the discovery, therapeutics, and diagnostics of microbes, and the changes in the lifestyles of human beings and the environment. However, challenges related to manufacturing and formulation are hindering the market growth. The holistic analysis of the drivers & challenges will help in deducing end goals and refining marketing strategies to gain a competitive edge. The microbial products market analysis report also provides detailed information on other upcoming trends that will have a far-reaching effect on the market growth.
Company Profiles
The microbial products market is fragmented and the vendors are deploying growth strategies such as forming strategic partnerships to compete in the market. Some of the companies covered in this report are bioMerieux SA, GlaxoSmithKline Plc, Kyowa Hakko Bio Co. Ltd., Merck KGaA, NovaMedica, Novartis AG, Pfizer Inc., Sanofi SA, Thermo Fisher Scientific Inc., and Valent BioSciences LLC, etc.
Few companies with key offerings
- bioMerieux SA – The company offers microbial products that provide diagnostic solutions for infectious diseases, cancer screening, and monitoring and cardiovascular emergencies that determine the source of disease and contamination to improve patient health and ensure consumer safety, under the brand name of bioMerieux SA.
- GlaxoSmithKline Plc – The company offers microbial products that discover, develop, manufactures, and markets human health products for major disease areas such as asthma, cancer, infections, diabetes, and mental health, under the brand name of GlaxoSmithKline plc.
- Kyowa Hakko Bio Co. Ltd. – The company offers microbial products that provide specialty chemical products, which manufactures and sells amino acids and nucleic acids for pharmaceutical and industrial use, under the brand name of Kyowa Hakko Bio Co. Ltd.
- Merck KGaA – The company offers microbial products that provide personalized treatments for serious diseases which include endocrinology, fertility, general medicine, neurology and immunology, oncology, and many more, under the brand name of Merck KGaA.
- NovaMedica – The company offers microbial products that provide antivirus, anti-inflammatory therapy, treatment of ophthalmic diseases and epilepsy as well as innovative technologies to detect oncological and infectious diseases, under the brand name of NovaMedica
Competitive Analysis
The competitive scenario provided in the microbial products market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.
Market Segmentation
- By Application, the market is classified into pharmaceutical, diagnostics, and biotechnology.
- By Geography, the market is classified as North America, Europe, Asia, and ROW.
Related Reports –
Microbial Testing Market –The microbial testing market has the potential to grow by USD 2.21 billion during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 7.75%. Download a free sample now!
Antimicrobial Susceptibility Testing Market –The antimicrobial susceptibility testing market has the potential to grow by USD 936.87 mn during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 5%. Download a free sample now!
| Microbial Products Market Scope | |
| Report Coverage | Details |
| Page number | 120 |
| Base year | 2021 |
| Forecast period | 2022-2026 |
| Growth momentum & CAGR | Accelerate at a CAGR of 12.20% |
| Market growth 2022-2026 | USD 18.41 billion |
| Market structure | Fragmented |
| YoY growth (%) | 11.07 |
| Regional analysis | North America, Europe, Asia, and ROW |
| Performing market contribution | North America at 41% |
| Key consumer countries | US, Canada, China, Germany, and UK |
| Competitive landscape | Leading companies, competitive strategies, consumer engagement scope |
| Companies profiled | bioMerieux SA, GlaxoSmithKline Plc, Kyowa Hakko Bio Co. Ltd., Merck KGaA, NovaMedica, Novartis AG, Pfizer Inc., Sanofi SA, Thermo Fisher Scientific Inc., and Valent BioSciences LLC |
| Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period, |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/41-of-growth-to-originate-from-north-america-for-microbial-products-market-evolving-opportunities-with-biomerieux-sa-glaxosmithkline-plc–kyowa-hakko-bio-co-ltd-17000-technavio-reports-301458440.html
SOURCE Technavio
